Canopy Growth
Sells cannabis products and Storz & Bickel vaporizers across Canadian and international medical markets.
Something off on this page? Send us feedback.
Profile
Sells adult-use and medical cannabis in Canada, serves international medical markets, and offers Storz & Bickel vaporization products. Its U.S. THC assets are held through unconsolidated Canopy USA.
Canadian adult-use and medical cannabis, international medical cannabis, and Storz & Bickel vaporization products make up the operating platform. The Canadian business serves adult-use and medical customers, while international operations serve medical-cannabis markets. Storz & Bickel manufactures and sells vaporization devices within its operating platform.
Operations are centered in Canada but extend to international medical-cannabis markets. The U.S. THC portfolio sits within Canopy USA, which holds Acreage, Wana, and a majority interest in Jetty but is unconsolidated from Canopy Growth’s results. That separation is a defining structural fact of the business.
Company facts
Categories
Key statistics
Year to date −15.2% · Average volume (30d) 3.5M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Nov 10, 2025 | Benchmark | Upgrade | Sell | Hold |
| Nov 10, 2025 | The Benchmark Company | Upgrade | Sell | Hold |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026Q1 FY27 | −$0.04 | −$0.02 | +50.0% | $58.2M | $57.2M | −1.8% | +4.07% |
| Jun 15, 2026Q4 FY26 | −$0.06 | −$0.17 | −183.3% | $53.4M | $51.2M | −4.1% | −2.53% |
| May 29, 2026Q4 FY26 | −$0.06 | −$0.94 | −1,466.7% | $53.4M | — | — | −0.92% |
| Feb 6, 2026Q3 FY26 | −$0.03 | −$0.10 | −233.3% | $51.6M | $54.3M | +5.2% | −0.91% |
Financial highlights
| 12 quarters | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|
| Revenue | $46.8M | $51.9M | $48.0M | $73.6M | $51.2M | $58.4M | |
| Gross profit | $7.6M | $13.0M | $15.8M | $21.2M | $5.9M | $16.0M | |
| Operating income | −$3.2M | −$16.3M | −$12.2M | −$26.0M | −$19.8M | −$15.9M | |
| Net income | −$158.8M | −$29.9M | −$1.2M | −$61.8M | −$113.0M | −$10.5M | |
| Diluted EPS | −$1.03 | −$0.16 | −$0.00 | −$0.18 | −$0.29 | −$0.02 | |
| Gross margin | 16.2% | 25.0% | 32.8% | 28.8% | 11.6% | 27.4% | |
| Operating margin | -6.7% | -31.4% | -25.3% | -35.3% | -38.6% | -27.2% |
Fiscal years (4-quarter sums)FY22 $253.5M · FY23 $214.4M · FY24 $213.7M · FY25 $193.5M · FY26 $224.7M
Revenue by product · FY25
Revenue by geography · Q1 FY27
Balance sheet, Jun 30, 2026Cash & short-term investments $245.8M · Total debt $199.5M · Total assets $794.1M · Shareholders' equity $495.4M
Dividends
No dividends on record.
Ownership
Shares outstanding 422.15M · Float 415.29M · 98.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Toroso Investments, LLC | 9.19M | 2.18% | 13F | Aug 13, 2026 |
| Morgan Stanley | 1.95M | 0.46% | 13F | Aug 13, 2026 |
| Lazard Asset Management LLC | 1.85M | 0.44% | 13F | Aug 14, 2026 |
| Luc Mongeau · director, officer: Chief Executive Officer | 1.72M | 0.41% | Form 4 | Jun 22, 2026 |
| Jane Street Group, LLC | 1.56M | 0.37% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 24, 2026 | Thomas Carlton Stewart | officer: See Remarks | −2,231 | $1.47 |
| Aug 24, 2026 | Christelle Gedeon | officer: See Remarks | −13,344 | $1.47 |
| Jun 26, 2026 | David Angelo Lazzarato | director | −22,674 | $0.9237 |
| Jun 26, 2026 | M. Shan Atkins | director | −3,197 | $0.9237 |
| Jun 26, 2026 | Theresa Yanofsky | director | −15,054 | $0.9237 |
Peers
- Tilray Brands
Canadian adult-use, medical, and international cannabis overlap
- Aurora Cannabis
Canadian and international medical-cannabis overlap
- Organigram Global
Canadian adult-use cannabis and international sales overlap
- Cronos Group
Canadian adult-use cannabis and international medical overlap
- SNDL
Canadian cannabis production, brands, and retail overlap
- Village Farms International
Canadian cannabis flower and international exports overlap
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Canopy Growth | $0.9900 | −1.88% | $421.9M | — | — | 0.8 | +8.4% |
| Tilray Brands | $4.59 | +0.17% | $513.3M | — | — | 0.4 | +25.5% |
| Aurora Cannabis | $4.01 | +0.25% | $248.4M | — | — | 1.2 | −26.5% |
| Organigram Global | $1.20 | −1.99% | $171.0M | 2.7 | 49.6 | 0.7 | +43.3% |
| Cronos Group | $3.38 | +0.14% | $1.26B | 18.7 | 56.3 | 7.0 | +63.8% |
| SNDL | $1.36 | 0.00% | $352.7M | — | — | 0.5 | −7.6% |
| Village Farms International | $2.95 | +1.90% | $354.5M | 15.5 | 14.6 | 1.5 | +6.8% |
| Median | 15.5 | 49.6 | 1.0 | +16.2% |